Eosinophilic Myocarditis
Eosinophilic myocarditis is an uncommon and diverse type of inflammatory heart disease that may manifest with varying levels of severity. Protheragen, a primary service provider, aids in providing research-related services for rare cardiovascular diseases such as eosinophilic myocarditis. In every facet of drug research and innovation, our company integrates useful knowledge and advanced technology which allows for customer needs in fulfilling standards and requirements.
Overview of Eosinophilic Myocarditis
Eosinophilic myocarditis is a rare type of myocarditis that involves eosinophilic infiltration of the myocardium and usually has an accompanying eosinophilia. Although infrequent, eosinophilic myocarditis carries the risk for life-threatening manifestations; it may present as mild asymptomatic disease or progress to multifocal extensive infiltrative processes with necrosis, thrombotic processes, and endomyocardial fibrosis.
Fig.1 Manifestations of eosinophilic myocarditis. (Piccirillo, F., et al., 2024)Pathogenesis of Eosinophilic Myocarditis
Eosinophilic myocarditis develops mainly due to the cell membrane damage and destruction caused by eosinophils due to their release of related substances. Out of numerous possible underlying eosinophilia-causing factors, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES) along with some reactive hypersensitivity processes are the most prominent.
Fig.2 Pathophysiology of eosinophilic myocarditis. (Piccirillo, F., et al., 2024)Therapeutics Development for Eosinophilic Myocarditis
| Drug Names | Mechanism of Action | Targets | Research Phase |
|---|---|---|---|
| MoAbs | Inhibit the migration of eosinophils to the heart while controlling focal fibrosis of the cardiac muscle. | CD18, ICAM-1, VLA-4 | Preclinical |
| Soluble ST2 | Inhibit eosinophilia and support improvement in systolic function. | ST2 | Preclinical |
| mCAN10 | Obliteration of IL1RAP mitigated the severity of autoimmune myocarditis and staved off exacerbation in the functional capacity of the heart. | IL1RAP | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen provides an all-encompassing approach to drug development by incorporating diagnostics, therapeutics as well as specific disease modeling. All of our critical preclinical services such as pharmacokinetics and drug safety assessments are seamlessly integrated into one cohesive platform. This enables our clients to form a one-stop strategy that optimizes the path from testing to implementation.
Therapeutic Development Services
Animal Model Development for Eosinophilic Myocarditis
The use of animal models enables the study of unique features of different types of eosinophilic myocarditis. Our company focuses on providing one-of-a-kind services that involve creating specifically tailored animal models to facilitate research on eosinophilic myocarditis and other rare heart diseases. By collaborating closely with our clients, we ensure that each model is precisely engineered to meet specific research needs.
Genetically Engineered Animal Model
Genetically engineered animal models of eosinophilic myocarditis involve gene modifications to induce chronic eosinophilia leading to myocardial damage.
Optional models:
- IFNγ-/-/IL17A-/- model
- Other models
- Bcl-6 deficient model
Induced Animal Model Development
The induced model involves the induction of specific antigens and allergic or parasitic response to result in myocarditis characterized by eosinophilic infiltration.
Optional models:
- Toxocariasis-infected model
- Animal model of adoptive transferred myocarditis
- Coxsackievirus B3 (CVB3)-induced model
- Other models
Through advanced technology and our proprietary industry knowledge, Protheragen stands out in pioneering research on uncommon cardiovascular conditions. We take pride in offering complete solutions to integrated systems that improve the efficacy taken in the development of drugs and the accuracy of new therapeutics. Should you require these services, kindly reach out to us.
References
- Piccirillo, Francesco et al. "Eosinophilic Myocarditis: From Bench to Bedside." Biomedicines 12.3 (2024): 656.
- Asada, Ashlee M et al. "Eosinophilic Myocarditis: A Concise Review." Current cardiology reports 27.1 (2025): 38.
For research use only, not for clinical use.